General Information of DTT (ID: TTQ13FT)

DTT Name T-cell-specific surface glycoprotein CD28 (CD28) DTT Info
Gene Name CD28

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Belatacept DMXLYQF Kidney transplant rejection NE84 Approved [1]
------------------------------------------------------------------------------------
11 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AB-103 DMPDQ8T Necrotizing soft tissue infection 1B71 Phase 3 [2]
Lulizumab pegol DMGWZ93 Systemic lupus erythematosus 4A40.0 Phase 2 [3]
AU101 DMLAKPI Osteosarcoma 2B51 Phase 1/2 [4]
REGN5668 DMH1UV5 Ovarian cancer 2C73 Phase 1/2 [5]
REGN5678 DM0Y6WU Prostate cancer 2C82.0 Phase 1/2 [6]
CD19-CAR and CD28-CAR T Cells DMUR1MN Acute lymphoblastic leukaemia 2A85 Phase 1 [7]
CD28 and CD137 CAR-T Cells DMFGQXB Acute lymphoblastic leukaemia 2A85 Phase 1 [8]
RG6333 DM1BRF2 Non-hodgkin lymphoma 2B33.5 Phase 1 [9]
RO7443904 DMSWZNU Non-hodgkin lymphoma 2B33.5 Phase 1 [10]
SAR442257 DMXD5QP Malignant neoplasm 2A00-2F9Z Phase 1 [11]
SAR443216 DMUQNG6 Gastric cancer 2B72 Phase 1 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
TGN-1412 DMELNA8 Autoimmune diabetes 5A10 Discontinued in Phase 1 [13]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anti-CD28 DM5BH7J Immune System disease 4A01-4B41 Investigative [14]
FR-104 DM7UP4E Autoimmune diabetes 5A10 Investigative [14]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
6 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
7 ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
8 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
9 Clinical pipeline report, company report or official report of Roche
10 Clinical pipeline report, company report or official report of Genentch
11 Clinical pipeline report, company report or official report of Sanofi.
12 Clinical pipeline report, company report or official report of Sanofi
13 TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863).